Dr. Cookson on current and future advancement in GU cancer care
“We’re [going to] have a whole new era of immune therapies and different novel ways to treat [patients], and then [utilize] combinations of these therapies,” says Michael S. Cookson, MD, MMHC, FACS.
In this video, the Society of Urologic Oncology’s (SUO) Past President Michael S. Cookson, MD, MMHC, FACS, discusses general advancements in genitourinary cancer that were presented at the 2021 SUO Annual Meeting. Cookson is a professor and the Donald D. Albers endowed chair in urology at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
